Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
July 25, 2016
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice
Selvi Durmus, Stéphanie van Hoppe, Alfred H Schinkel
Advances in Cancer Research
|
February 3, 2015
Apical ABC transporters and cancer chemotherapeutic drug disposition
Selvi Durmus, Jeroen J M A Hendrikx, Alfred H Schinkel
Expert Opinion on Drug Discovery
|
December 16, 2020
CRISPRing future medicines
Laure Grand Moursel, Mijke Visser, Geraldine Servant, et al.
RNA (New York, N.Y.)
|
April 29, 2010
MicroRNAs, macrocontrol: regulation of miRNA processing
Izabella Slezak-Prochazka, Selvi Durmus, Bart-Jan Kroesen, et al.
Molecular Pharmaceutics
|
October 2, 2012
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Selvi Durmus, Rolf W Sparidans, Els Wagenaar, et al.
International Journal of Cancer
|
February 21, 2014
In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters
Selvi Durmus, Jyoti Naik, Levi Buil, et al.
Journal of Inorganic Biochemistry
|
September 5, 2015
Cationic Pd(II)/Pt(II) 5,5-diethylbarbiturate complexes with bis(2-pyridylmethyl)amine and terpyridine: Synthesis, structures,DNA/BSA interactions, intracellular distribution, cytotoxic activity and induction of apoptosis
Ceyda Icsel, Veysel T Yilmaz, Yunus Kaya, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
November 13, 2013
Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma
Rolf W Sparidans, Selvi Durmus, Alfred H Schinkel, et al.
Pharmaceutical Research
|
January 8, 2015
Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)
Anita Kort, Selvi Durmus, Rolf W Sparidans, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
March 30, 2013
Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma
Rolf W Sparidans, Selvi Durmus, Alfred H Schinkel, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
July 25, 2016
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice
Selvi Durmus, Stéphanie van Hoppe, Alfred H Schinkel
Advances in Cancer Research
|
February 3, 2015
Apical ABC transporters and cancer chemotherapeutic drug disposition
Selvi Durmus, Jeroen J M A Hendrikx, Alfred H Schinkel
Expert Opinion on Drug Discovery
|
December 16, 2020
CRISPRing future medicines
Laure Grand Moursel, Mijke Visser, Geraldine Servant, et al.
RNA (New York, N.Y.)
|
April 29, 2010
MicroRNAs, macrocontrol: regulation of miRNA processing
Izabella Slezak-Prochazka, Selvi Durmus, Bart-Jan Kroesen, et al.
Molecular Pharmaceutics
|
October 2, 2012
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Selvi Durmus, Rolf W Sparidans, Els Wagenaar, et al.
International Journal of Cancer
|
February 21, 2014
In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters
Selvi Durmus, Jyoti Naik, Levi Buil, et al.
Journal of Inorganic Biochemistry
|
September 5, 2015
Cationic Pd(II)/Pt(II) 5,5-diethylbarbiturate complexes with bis(2-pyridylmethyl)amine and terpyridine: Synthesis, structures,DNA/BSA interactions, intracellular distribution, cytotoxic activity and induction of apoptosis
Ceyda Icsel, Veysel T Yilmaz, Yunus Kaya, et al.
Journal of Pharmaceutical and Biomedical Analysis
|
November 13, 2013
Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma
Rolf W Sparidans, Selvi Durmus, Alfred H Schinkel, et al.
Pharmaceutical Research
|
January 8, 2015
Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)
Anita Kort, Selvi Durmus, Rolf W Sparidans, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
March 30, 2013
Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma
Rolf W Sparidans, Selvi Durmus, Alfred H Schinkel, et al.
Page
of 2